Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

First Murder By Propofol Reported By Leading Anesthesia Journal
Recent questions about the death of Michael Jackson have focused media attention on the commonly used intravenous anesthetic propofol. In the April 2009 issue of Anesthesia & Analgesia, the leading clinical journal for anesthesiologists, Robert R. Kirby, James M. Colaw and Michael M. Douglas reported on a 24-year-old woman whose 2005 death was attributed to propofol toxicity.
generic viagra online
New Therapy Improves Chances Of Living Disease-free With Difficult-to-treat Childhood Cancer
A phase III study has shown that adding an antibody-based therapy that harnesses the body"s immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma. Neuroblastoma, a hard-to-treat cancer arising from nervous system cells, is responsible for 15 percent of cancer-related deaths in children. The researchers reported their findings - the first to show that immunotherapy could be effective against childhood cancer - online May 14, 2009 on the American Society of Clinical Oncology website in advance of presentation June 2.
News of the day
Washington's Basic Health Plan Raises Rates To Compensate For Budget Cuts
Washington state"s cash-strapped health insurance program, Basic Health Plan, "is resorting to steep premium increases to achieve what [its officials] were loath to do on their own - expel thousands of working-class people," the Seattle Times reports. Price hikes for the poorest plan members - who earn less than 125 percent of the poverty line - could double their premiums, while spikes are expected to be much higher for members with bigger incomes.
Health Insurance

Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells

Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand have found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as primary myeloid and lymphoid leukemic blast cells undergo programmed cell death when exposed briefly to the investigational anti-tumor drug phenoxodiol. These results make phenoxodiol a promising candidate for the treatment of pathologically activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as autoimmune diseases and graft-versus-host disease, according to an article published in the Haematologica Journal on June 16, 2009, http://www.haematologica.org/cgi/reprint/94/7/928. The researchers demonstrated that phenoxodiol inhibited plasma membrane electron transport and cell proliferation and promoted apoptosis of rapidly proliferating human T-cells, induced to undergo rapid proliferation by exposure to cells from an incompatible donor, but at the same time it did not affect normal resting T-cells. "These findings indicate that phenoxodiol may have utility against autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as having potential in management of graft rejection in transplantation patients," said Prof. Alan Husband, Group Director of Research, Marshall Edwards, Inc. "We"re appreciative of Dr. Patries Herst and colleagues for undertaking this important research." About phenoxodiol Phenoxodiol is being developed by the U.S. oncology company Marshall Edwards, Inc. (NASDAQ: MSHL) as a chemosensitizing agent in combination with platinum drugs for late stage, chemoresistant ovarian cancer and as a monotherapy for prostate and cervical cancers. It has a unique mechanism of action, binding to cancer cells via a surface oxidase, disrupting membrane electron transport and causing major downstream disturbances in expression of proteins necessary for cancer cell survival and responsible for the development of drug resistance. In cancer cells, phenoxodiol appears to inhibit selectively the pro-survival regulator known as S-1-P (sphingosine-1-phosphate) that is overexpressed in cancer cells. In response to phenoxodiol, the S-1-P content in cancer cells is decreased, rendering those cells more sensitive to chemotherapy. Indeed, in laboratory studies, it has been demonstrated that cancer cells pre-treated with phenoxodiol were killed with lower doses of chemotherapy drugs. Importantly, phenoxodiol has been shown not to affect adversely normal cells in animal and laboratory testing. Phenoxodiol is being investigated as a therapy for late-stage, chemoresistant ovarian, prostate and cervical cancers. Phenoxodiol has received Fast Track status from the FDA to facilitate its development as a therapy for recurrent ovarian and prostate cancers. Phenoxodiol is an investigational drug and, as such, is not commercially available. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by FDA as being safe and effective for the intended use. Phenoxodiol is the first of a family of compounds in the Marshall Edwards, Inc. drug pipeline of flavonoid derivatives. Marshall Edwards, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009